Last updated on May 2015

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury


Brief description of study

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

Detailed Study Description

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study. Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects. The day of infusion will be considered day zero. From that moment, followup will be divided into 2,7,14 days. Clinical results will be analyzed after completion of 14 days of followup.

Clinical Study Identifier: NCT02444455

Contact Investigators or Research Sites near you

Start Over

Changqing Bai, M.D.

Department of Respiration,Affiliated Hospital to Academy of Military Medical Sciences
Beijing, China
  Connect »